A randomized clinical trial of autologous platelet-rich plasma in the treatment of mandibular degree II furcation defects

2009 ◽  
Vol 36 (7) ◽  
pp. 581-588 ◽  
Author(s):  
Avani Rangaraju Pradeep ◽  
Sujatha Pai ◽  
Garima Garg ◽  
Prapulla Devi ◽  
Sharath Kumara Shetty
Keyword(s):  
Clinical Trial ◽  
Randomized Clinical Trial ◽  
Platelet Rich Plasma ◽  
Furcation Defects ◽  
Autologous Platelet Rich Plasma ◽  
Autologous Platelet

scholarly journals Regenerative Effect of Intraovarian Injection of Activated Autologous Platelet Rich Plasma: Serum Anti-Mullerian Hormone Levels Measured Among Poor-Prognosis In Vitro Fertilization Patients

2020 ◽  
pp. 1-5 ◽  
Author(s):  
E. Scott Sills ◽  
E. Scott Sills ◽  
J. L. Petersen ◽  
N. S. Rickers ◽  
Samuel H. Wood ◽  
...  
Keyword(s):  
Clinical Trial ◽  
In Vitro Fertilization ◽  
Platelet Rich Plasma ◽  
Ovarian Tissue ◽  
Ovarian Response ◽  
Vitro Fertilization ◽  
Autologous Platelet Rich Plasma ◽  
Pre Treatment ◽  
Autologous Platelet

This registered, prospective clinical trial assessed serum anti-Mullerian hormone (AMH) patterns after treatment with activated platelet rich plasma (PRP). Patients with low ovarian reserve and/or at least 1 prior failed in vitro fertilization (IVF) cycle (n=182) received PRP injected into ovarian tissue under ultrasound guidance. Pretreatment AMH, BMI and platelet (PLT) concentration were recorded and serum AMH, follicle stimulating hormone, and estradiol were then measured at 2-week intervals for up to three months. Mean±SD patient age was 45.4±6.1yrs. Improved serum AMH was observed in 51 patients (28%) with median increase of 167% [95%CI 91; 280] after treatment; mean interval to maximum AMH increase was 4 weeks (range 2-10 weeks). Improved post-treatment AMH was not limited to younger patients; when stratified by age (<42 vs. ≥42yrs), significant AMH improvements were seen in both groups after treatment (p=0.03 and 0.009, respectively). Among responders, mean basal PLT count was higher (274K) vs. non-responders (250K); p<0.001. This is the first clinical trial to describe an intraovarian PRP technique for low reserve and finds the treatment safe and associated with significant increases in serum AMH for some patients, usually within four weeks. The substantially different pre-treatment PLT concentrations measured across PRP response groups warrants further investigation. Additional research can characterize ovarian response better, optimize PRP protocols, and collect outcomes data from those who subsequently undergo IVF with autologous oocytes.

Sign in / Sign up

Export Citation Format

Share Document